Rakete am Start ?

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier,   Sangamo's president and CEO, will provide an update on the progress of   Sangamo's ZFP Therapeutic® development programs and an overview of the   company's business strategy at 2:30 pm ET on Thursday, February 16, 2012, at the 2012 Leerink Swann Global Healthcare Conference which will be held in New York City.

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that new data from  its program to develop a 'functional cure' for  HIV/AIDS were described  in two presentations at the 19th Conference on Retroviruses and  Opportunistic Infections (CROI), held in Seattle from March 5 to March 8, 2012. 

"These data differentiate SB-728-T from other novel therapies as a feasible approach to controlling HIV/AIDS," said Ronald Mitsuyasu, M.D., Professor of Medicine, David Geffen School of Medicine at UCLA  and a principal investigator in Sangamo's SB-728-T studies.  "The  results suggest that SB-728-T has a positive effect on immune health of  HIV-infected patients and this effect is persistent for over a year in  some subjects.  Most importantly, SB-728-T treatment provides  HIV-resistant T-cells that are capable of mounting an immune response to  an inflammatory event in lymphoid tissues and has yielded encouraging  effects on HIV viral load when antiretroviral drugs are withdrawn during  a treatment interruption."

"These data add to our understanding of the positive viral load  changes in SB-728-T-treated subjects, and suggest that an early cytokine  burst may initiate the dramatic and prolonged increase in CD4 counts  observed following SB-728-T treatment," said Dale Ando,  M.D., Sangamo's vice president of therapeutic development and chief  medical officer. "They also confirm that SB-728-T meets key requirements  for our strategy for a 'functional cure' for HIV, by demonstrating  durable engraftment and prolonged trafficking and dynamic immunological  responsiveness in the gut mucosa.  Together, these data further validate  our strategy for the continued development of this ZFP Therapeutic as a  'functional cure' for HIV in two ongoing Phase 2 clinical trials  designed to extend the observation of a statistically significant  correlation between levels of bi-allelic modification of CD4 T cells and  viral load reductions during treatment interruptions in HIV infection.  The first study builds on the approximate doubling of bi-allelic  engraftment that can be achieved in CCR5 delta-32 heterozygotes and  seeks to confirm the occurrence of aviremia during treatment  interruption as observed in one such patient in our Phase 1 program.   The other clinical trial will examine the ability of a lymphopenic  preconditioning regimen to enhance bi-allelic engraftment, and reduce  viral load during treatment interruption, in non-CCR5-mutated HIV  subjects."